B6N(Cg)-Npffr2tm1.2Ics/Ieg
Status | Available to order |
EMMA ID | EM:15992 |
Citation information | RRID:IMSR_EM:15992 Research Resource Identifiers (RRID) are persistent unique ID numbers assigned to help researchers cite key resources (e.g. antibodies, model organisms and software projects) in the biomedical literature to improve transparency and reproducibility in research. See https://www.rrids.org/ for more information. |
International strain name | B6N(Cg)-Npffr2tm1.2Ics/Ieg |
Alternative name | Npffr2tm1.2Ics |
Strain type | Targeted Mutant Strains : Knock-out |
Allele/Transgene symbol | Npffr2tm1.2Ics |
Gene/Transgene symbol | Npffr2 |
Information from provider
Provider | Guillaume Pavlovic |
Provider affiliation | PHENOMIN-ICS |
Additional owner | Frederic Simonin, PhD. Directeur de Recherche CNRS, Team GPCR, pain and Inflammation. Biotechnology and Cellular Signalling, UMR7242. Institut du Médicament de Strasbourg ESBS , 300 Bvd Sebastien Brant CS10413 67412, Illkirch Cedex. FRANCE |
Genetic information | Npffr2 conditional knock-out heterozygotes were generated as described in the Supplementary Data of Waqas et al., 2017, Journal of Clinical Investigation (doi:10.1172/JCI90152). In brief, Npffr2 conditional knock-out mice were generated by designing a targeting vector in which exon 4 (as defined in ENSMUST00000048557) was flanked by loxP sites and a neomycin resistance cassette flanked by FRT sites. This construct was electroporated into C57BL/6N ES cells, G418-selected clones were screened by PCR and Southern blot, and a correctly targeted clone was used to produce chimeras. After breeding with FlpE-expressing mice to remove the neomycin cassette (Npffr2tm1.1Ics allele, EMMA strain ID EM:15983) and with CMV-cre-expressing mice to excise exon 4, Npffr2 knock-out animals were obtained (Npffr2tm1.2Ics allele). |
Phenotypic information | Homozygous:The mice are viable and born at Mendelian ratios, with no reported perinatal lethality. They are fertile, producing normal litter sizes without any observed breeding difficulties. Additionally, they are immunocompetent, showing no signs of immunodeficiency.Heterozygous:The mice are viable and born at Mendelian ratios, with no reported perinatal lethality. They are fertile, producing normal litter sizes without any observed breeding difficulties. Additionally, they are immunocompetent, showing no signs of immunodeficiency. |
Breeding history | Two successive breedings with C57BL/6NTac wild-type animals were performed to eliminate the flp transgene and to backcross onto the C57BL/6NTac background. The flp deleter animals (MGI:2448985 ID) used for selection cassette removal are described in Rodriguez et al., 2000, Nature Genetics (doi:10.1038/75973) and had a genetic background consisting of approximately 6% C57BL/6J and 94% C57BL/6NTac. The cre deleter mice (MGI:2177165) used for floxed exon excision were originally generated by microinjection of transgenic DNA into B6/SJL embryos, as described in Dupé et al., 1997, Development (doi:10.1242/dev.124.2.399) and had a background composed of approximately 1.5% C57BL/6J and 98.5% C57BL/6NTac. |
References |
|
Homozygous fertile | yes |
Homozygous viable | yes |
Homozygous matings required | no |
Immunocompromised | no |
Information from EMMA
Archiving centre | ICS, Institut Clinique de la Souris, Illkirch-Graffenstaden, France |
Literature references
- Neuropeptide FF increases M2 activation and self-renewal of adipose tissue macrophages.;Waqas Syed F Hassnain, Hoang Anh Cuong, Lin Ya-Tin, Ampem Grace, Azegrouz Hind, Balogh Lajos, Thuróczy Julianna, Chen Jin-Chung, Gerling Ivan C, Nam Sorim, Lim Jong-Seok, Martinez-Ibañez Juncal, Real José T, Paschke Stephan, Quillet Raphaëlle, Ayachi Safia, Simonin Frédéric, Schneider E Marion, Brinkman Jacqueline A, Lamming Dudley W, Seroogy Christine M, Röszer Tamás, ;2017;The Journal of clinical investigation;127;2842-2854; 28581443
Information on how we integrate external resources can be found here
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).